A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
A study for patients with renal cell cancer using study drug sorafenib
Sponsor: Aveo Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAQ6970
U.S. Govt. ID: NCT02627963
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to compare the effectiveness of tivozanib in renal cell cancer compared to an approved drug sorafenib which works in a similar way to tivozanib. Tivozanib and sorafenib are both called study medication. This study will also see whether tivozanib is safe and tolerable for patients with advanced renal cell cancer. This study will look at the effects of tivozanib on subjects with refractory advanced renal cell cancer.
This study is closed
Emerson Lim, MD
Do You Qualify?
Have you been diagnosed with renal cell cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator